Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy

A 65-year-old male with hepatocellular carcinoma experienced alopecia universalis after 21 months of treatment with Sintilimab, an anti-PD-1 antibody. Despite the extensive hair loss, the treatment led to a significant decrease in tumor markers and complete tumor remission, as confirmed by imaging and pathological examination. The case highlights that while immune checkpoint blockades can induce rare adverse events like alopecia areata, they can also result in effective anti-tumor responses. Continuation of PD-1 inhibitor treatment is recommended when it proves effective, regardless of alopecia development.